Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board
Advertisement
ZyVersa's lead anti-inflammatory candidate is a novel monoclonal antibody targeting the ASC component of inflammasomes, inhibiting both the intracellular and extracellular inflammatory response cascade for treatment of people with debilitating inflammatory diseases
